Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Single Dose MPCs · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| High Dose MPCs | EXPERIMENTAL | Injection of High Dose MPCs with Hyaluronic Acid |
| Low Dose MPCs | EXPERIMENTAL | Injection of Low Dose MPCs with Hyaluronic Acid |
| Saline injection | SHAM_COMPARATOR | Injection of saline solution. |
| Hyaluronic acid injection | PLACEBO_COMPARATOR | Injection of hyaluronic acid solution |
| Name | Type | Description |
|---|---|---|
| Single Dose MPCs Injection | BIOLOGICAL | Injection of Low Dose MPCs with Hyaluronic Acid into the degenerated lumbar disc's nucleus pulposus. |
| Single injection of saline solution | PROCEDURE | Intradiscal control injection with saline solution |
| Single injection of hyaluronic acid | PROCEDURE | Intradiscal control injection with hyaluronic acid |
Inclusion Criteria: 1. Male or females at least 18 years of age. 2. Have the ability to understand the requirements of the study, to provide written informed consent, and to comply with the study protocol. 3. Have the ability to understand and provide written authorization for the use and disclosur...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Mesoblast Limited Sponsored ADR | MESO | 1 | PHASE3 | Rexlemestrocel-L, HA mixture, Saline |
| Creative Medical Technology Holdings, Inc. | CELZ | 1 | PHASE1 | CELZ-201-DDT |
| Stryker Corporation | SYK | 2 | N/A | Undisclosed |
| Globus Medical Inc Class A | GMED | 6 | - | Undisclosed |
| Orthofix Medical, Inc. | OFIX | 1 | - | Undisclosed |
Single Dose MPCs is an investigational therapy being studied for the treatment of Degenerative Disc Disease, a condition that causes lumbar back pain. It is a mesenchymal precursor cell product developed by Mesoblast Limited. The therapy is currently in Phase 2 clinical development and has not been approved by regulatory authorities.
Single Dose MPCs is a cell therapy that uses mesenchymal precursor cells (MPCs) to target degenerative disc disease. These cells are intended to modulate the inflammatory environment and promote tissue repair within the intervertebral disc. The therapy is being evaluated for its safety and preliminary efficacy in reducing lumbar back pain associated with disc degeneration.
Single Dose MPCs is being developed by Mesoblast Limited, a biopharmaceutical company listed on the NASDAQ under the ticker symbol MESO. Mesoblast specializes in cell-based medicines and is conducting clinical trials to evaluate the safety and efficacy of this therapy for degenerative disc disease.
Single Dose MPCs is in Phase 2 clinical development. It is an investigational therapy and has not yet been approved by the FDA or other regulatory agencies. The Phase 2 trial has been completed, and the results will inform whether the therapy advances to later-stage clinical trials.
Single Dose MPCs has been studied in one completed Phase 2 clinical trial, identified by the identifier NCT01290367. This trial was titled 'Safety and Preliminary Efficacy Study of Mesenchymal Precursor Cells (MPCs) in Subjects With Lumbar Back Pain' and enrolled 100 participants with Degenerative Disc Disease in the United States and Australia.
Single Dose MPCs refers to a specific dosing regimen of mesenchymal precursor cells (MPCs) developed by Mesoblast. The clinical trial NCT01290367 evaluated the safety and preliminary efficacy of MPCs in subjects with lumbar back pain. The term 'Single Dose' indicates that the therapy is administered as a single injection, as opposed to multiple doses.